|
1
|
World Health Organization, . Obesity and
Overweight Fact. http://www.who.int/mediacentre/factsheets/fs311/en/January
5–2022
|
|
2
|
Gunter MJ and Leitzmann MF: Obesity and
colorectal cancer: Epidemiology, mechanisms and candidate genes. J
Nutr Biochem. 17:145–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arnold M, Pandeya N, Byrnes G, Renehan
PAG, Stevens GA, Ezzati M, Ferlay J, Miranda JJ, Romieu I, Dikshit
R, et al: Global burden of cancer attributable to high body-mass
index in 2012: A population-based study. Lancet Oncol. 16:36–46.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andersson TM, Weiderpass E, Engholm G,
Lund AQ, Olafsdottir E, Pukkala E, Stenbeck M and Storm H:
Avoidable cancer cases in the nordic countries-the impact of
overweight and obesity. Eur J Cancer. 79:106–118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Otani T, Iwasaki M and Inoue M; Shoichiro
Tsugane for the Japan Public Health Center-based Prospective Study
Group, : Body mass index, body height, and subsequent risk of
colorectal cancer in middle-aged and elderly Japanese men and
women: Japan public health center-based prospective study. Cancer
Causes Control. 16:839–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okabayashi K, Ashrafian H, Hasegawa H, Yoo
JH, Patel VM, Harling L, Rowland SP, Ali M, Kitagawa Y, Darzi A and
Athanasiou T: Body mass index category as a risk factor for
colorectal adenomas: A systematic review and meta-analysis. Am J
Gastroenterol. 107:1175–1186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kitahara CM, Berndt SI, de Gonzalez AB,
Coleman HG, Schoen RE, Hayes RB and Huang WY: Prospective
investigation of body mass index, colorectal adenoma, and
colorectal cancer in the prostate, lung, colorectal, and ovarian
cancer screening trial. J Clin Oncol. 31:2450–2459. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vermeulen L and Snippert HJ: Stem cell
dynamics in homeostasis and cancer of the intestine. Nat Rev
Cancer. 14:468–480. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Batlle E, Henderson JT, Beghtel H, van den
Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering
M, Pawson T and Clevers H: Beta-catenin and TCF mediate cell
positioning in the intestinal epithelium by controlling the
expression of EphB/ephrinB. Cell. 111:251–263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boyd AW, Bartlett PF and Lackmann M:
Therapeutic targeting of EPH receptors and their ligands. Nat Rev
Drug Discov. 13:39–62. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chukkapalli S, Amessou M, Dilly AK, Dekhil
H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA,
et al: Role of the EphB2 receptor in autophagy, apoptosis and
invasion in human breast cancer cells. Exp Cell Res. 320:233–246.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv J, Xia Q, Wang J, Shen Q, Zhang J and
Zhou X: EphB4 promotes the proliferation, invasion, and
angiogenesis of human colorectal cancer. Exp Mol Pathol.
100:402–408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oweida A, Bhatia S, Hirsch K, Calame D,
Griego A, Keysar S, Pitts T, Sharma J, Eckhardt G, Jimeno A, et al:
Ephrin-B2 overexpression predicts for poor prognosis and response
to therapy in solid tumors. Mol Carcinog. 56:1189–1196. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clevers H and Batlle E: EphB/EphrinB
receptors and Wnt signaling in colorectal cancer. Cancer Res.
66:2–5. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cortina C, Palomo-Ponce S, Iglesias M,
Fernández-Masip JL, Vivancos A, Whissell G, Humà M, Peiró N,
Gallego L, Jonkheer S, et al: EphB-ephrin-B interactions suppress
colorectal cancer progression by compartmentalizing tumor cells.
Nat Genet. 39:1376–1383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herath NI and Boyd AW: The role of Eph
receptors and ephrin ligands in colorectal cancer. Int J Cancer.
126:2003–2011. 2010.PubMed/NCBI
|
|
17
|
Guo DL, Zhang J, Yuen ST, Tsui WY, Chan
AS, Ho C, Ji J, Leung SY and Chen X: Reduced expression of EphB2
that parallels invasion and metastasis in colorectal tumours.
Carcinogenesis. 27:454–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mori T, Maeda N, Inoue K, Sekimoto R,
Tsushima Y, Matsuda K, Yamaoka M, Suganami T, Nishizawa H, Ogawa Y,
et al: A novel role for adipose ephrin-B1 in inflammatory response.
PLoS One. 8:e761992013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gohda T, Tanimoto M, Kaneko S, Shibata T,
Funabiki K, Horikoshi S and Tomino Y: Minor gene effect of leptin
receptor variant on the body weight in KK/Ta mice. Diabetes Obes
Metab. 8:581–584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakamura M and Yamada K: Studies on a
diabetic (KK) strain of the mouse. Diabetologia. 3:212–221. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang YP, Wu XH, Shi B, Wu WX and Yin GR:
Expression of chemokine CXCL12 and its receptor CXCR4 in human
epithelial ovarian cancer: An independent prognostic factor for
tumor progression. Gynecol Oncol. 103:226–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi T, Shiraishi A, Murata J,
Matsubara S, Nakaoka S, Kirimoto S and Osawa M: Muscarinic receptor
M3 contributes to intestinal stem cell maintenance via
EphB/ephrin-B signaling. Life Sci Alliance. 4:e2020009622021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oshima H, Oshima M, Kobayashi M, Tsutsumi
M and Taketo MM: Morphological and molecular processes of polyp
formation in Apc(delta716) knockout mice. Cancer Res. 57:1644–1649.
1997.PubMed/NCBI
|
|
25
|
Shih IM, Wang TL, Traverso G, Romans K,
Hamilton SR, Ben-Sasson S, Kinzler KW and Vogelstein B: Top-down
morphogenesis of colorectal tumors. Proc Natl Acad Sci USA.
98:2640–2645. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lugli A, Spichtin H, Maurer R, Mirlacher
M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G,
Kallioniemi OP, et al: EphB2 expression across 138 human tumor
types in a tissue microarray: High levels of expression in
gastrointestinal cancers. Clin Cancer Res. 11:6450–6458. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jubb AM, Zhong F, Bheddah S, Grabsch HI,
Frantz GD, Mueller W, Kavi V, Quirke P, Polakis P and Koeppen H:
EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res.
11:5181–5187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alazzouzi H, Davalos V, Kokko A, Domingo
E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espin E, Armengol M,
et al: Mechanisms of inactivation of the receptor tyrosine kinase
EPHB2 in colorectal tumors. Cancer Res. 65:10170–10173. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang P, Chu T, Dedousis N, Mantell BS,
Sipula I, Li L, Bunce KD, Shaw PA, Katz LS, Zhu J, et al: DNA
methylation alters transcriptional rates of differentially
expressed genes and contributes to pathophysiology in mice fed a
high fat diet. Mol Metab. 6:327–339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xiao Z, Carrasco R, Kinneer K, Sabol D,
Jallal B, Coats S and Tice DA: EphB4 promotes or suppresses
Ras/MEK/ERK pathway in a context-dependent manner: Implications for
EphB4 as a cancer target. Cancer Biol Ther. 13:630–637. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qu F, Song Y, Wu Y, Huang Y, Zhong Q,
Zhang Y, Fan Z and Xu C: The protective role of Ephrin-B2/EphB4
signaling in osteogenic differentiation under inflammatory
environment. Exp Cell Res. 400:1125052021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Azushima K, Tamura K, Wakui H, Maeda A,
Ohsawa M, Uneda K, Kobayashi R, Kanaoka T, Dejima T, Fujikawa T, et
al: Bofu-tsu-shosan, an oriental herbal medicine, exerts a
combinatorial favorable metabolic modulation including
antihypertensive effect on a mouse model of human metabolic
disorders with visceral obesity. PLoS One. 8:e755602013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heaberlin JR, Ma Y, Zhang J, Ahuja SS,
Lindsey ML and Halade GV: Obese and diabetic KKAy mice show
increased mortality but improved cardiac function following
myocardial infarction. Cardiovasc Pathol. 22:481–487. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nonogaki K, Hazama M and Satoh N:
Liraglutide suppresses obesity and hyperglycemia associated with
increases in hepatic fibroblast growth factor 21 production in KKAy
mice. Biomed Res Int. 2014:7519302014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Surawska H, Ma PC and Salgia R: The role
of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev.
15:419–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
